Ambrx allies with Chinese firms to develop breast cancer drug

06/21/2013 | Pharmaceutical Business Review Online

Ambrx agreed to collaborate with Chinese firms Zhejiang Medicine and WuXi PharmaTech in the development and marketing of the antibody drug conjugate ARX788 for treatment of HER2-positive breast cancer. Zhejiang will shoulder the development costs and will get the right to market the drug in China. WuXi will provide development and production services for the toxin, antibody and ADC.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA